Disease-modifying therapies targeting tau pathology beyond anti-amyloid approaches

The literature is heavily weighted toward amyloid-centric mechanisms and anti-inflammatory approaches (as evidenced by the GM-CSF trial), but specific therapeutic strategies targeting tau hyperphosphorylation, oligomerization, or propagation remain underdeveloped in the represented evidence.